Abstract: In a power conversion system, a control circuit has, as its operation modes: a first control mode in which control circuit controls a DC-DC converter at a first drive frequency; a second control mode in which control circuit controls DC-DC converter at a second drive frequency higher than first drive frequency; and a third control mode in which control circuit controls DC-DC converter at a third drive frequency higher than first drive frequency. Control circuit is configured to change operation mode from first control mode into second control mode when detector circuit detects a predetermined change in output voltage while control circuit is operating in first control mode. Control circuit controls DC-DC converter in third control mode in a process of changing, in response to detection of predetermined change, operation mode from first control mode into second control mode before starting to control DC-DC converter in second control mode.

Abstract: The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).

Abstract: The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).

Abstract: The present invention provides compounds of Formula (I): or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R 6, R7, R12, RXX, Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): wherein X1, X2, X3, X4, X5, X6, X7, Y, Rc, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.

Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.

Abstract: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms.

Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.

Abstract: The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).

Abstract: The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).

Abstract: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms.

Abstract: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms.

Abstract: A chemical treating system includes a main row or line of equally spaced, equal length chemical treatment workstations for sequentially treating a workpiece such as the cylinder bore of an internal combustion engine cylinder. Additional longer chemical treatment workstations are located transversely of the main row of workstations so that larger workstations can be included in the chemical treatment system without increasing the total length of the main row of workstations. By locating the longer workstations transversely of the main row, equal distances between the main row of workstations can be maintained by using work transfer devices that move the workpieces longitudinally along the main row and transversely to the additional chemical treatment workstations in a sequential process. At the transversely located workstation, an airblower is provided to remove residual chemical treatment solution from the workpieces before they are returned to the main line of workstations.